Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Sung-Woon Kim  (Kim SW) 3 Articles
Others
Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus
Sejeong Park, So Young Park, Yu Jin Kim, Soo Min Hong, Suk Chon, Seungjoon Oh, Jeong-taek Woo, Sung-Woon Kim, Young Seol Kim, Sang Youl Rhee
Diabetes Metab J. 2016;40(3):240-247.   Published online April 5, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.3.240
  • 5,213 View
  • 61 Download
  • 5 Web of Science
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM.

Methods

Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms.

Results

A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (P<0.001). The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05). However, there were no significant changes in symptoms associated with irritable bowel syndrome, diarrhea, and anal incontinence. No severe adverse events were reported throughout the study.

Conclusion

Rebamipide treatment for 12 weeks improved atypical GI symptoms in patients with T2DM.

Citations

Citations to this article as recorded by  
  • Effectiveness of Rebamipide as a part of the Helicobacter pylori eradication therapy in Russia: a meta-analysis of controlled trials
    Dmitry N. Andreev, Igor V. Maev, Dmitry S. Bordin, Svetlana V. Lyamina, Diana T. Dicheva, Aleksei K. Fomenko, Armine S. Bagdasarian
    Consilium Medicum.2022; 24(5): 333.     CrossRef
  • Сompliance in patients with coronary heart disease and erosive-ulcerative gastroduodenopathy
    A. R. Molchanova, A. I. Dolgushina, A. A. Seljanina
    Experimental and Clinical Gastroenterology.2020; (6): 82.     CrossRef
  • Rebamipide: evidence base for use in gastroenterology
    D. N. Andreev, I. V. Maev
    Terapevticheskii arkhiv.2020; 92(12): 97.     CrossRef
  • Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis
    Mohamed Hasif Jaafar, Sher Zaman Safi, Maw-Pin Tan, Sanjay Rampal, Sanjiv Mahadeva
    Digestive Diseases and Sciences.2018; 63(5): 1250.     CrossRef
  • Letter: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2016;40:240-7)
    Jin Hwa Kim
    Diabetes & Metabolism Journal.2016; 40(4): 334.     CrossRef
  • Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)
    Sejeong Park, So Young Park, Sang Youl Rhee
    Diabetes & Metabolism Journal.2016; 40(4): 336.     CrossRef
Risk Factors for the Progression of Intima-Media Thickness of Carotid Arteries: A 2-Year Follow-Up Study in Patients with Newly Diagnosed Type 2 Diabetes
Sang Ouk Chin, Jin Kyung Hwang, Sang Youl Rhee, Suk Chon, You-Cheol Hwang, Seungjoon Oh, Kyu Jeung Ahn, Ho Yeon Chung, Jeong-taek Woo, Sung-Woon Kim, Young Seol Kim, Ja-Heon Kang, In-Kyung Jeong
Diabetes Metab J. 2013;37(5):365-374.   Published online October 17, 2013
DOI: https://doi.org/10.4093/dmj.2013.37.5.365
  • 4,739 View
  • 31 Download
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Intima-media thickness (IMT) of the carotid arteries is known to have a positive correlation with the risk of cardiovascular disease. This study was designed to identify risk factors affecting the progression of carotid IMT in patients with type 2 diabetes mellitus (T2DM).

Methods

Patients with newly diagnosed T2DM with carotid IMT measurements were enrolled, and their clinical data and carotid IMT results at baseline and 2 years later were compared.

Results

Of the 171 patients, 67.2% of males and 50.8% of females had abnormal baseline IMT of the left common carotid artery. At baseline, systolic blood pressure, body mass index and smoking in male participants, and fasting plasma glucose and glycated hemoglobin levels in females were significantly higher in patients with abnormal IMT than in those with normal IMT. Low density lipoprotein cholesterol (LDL-C) levels in males and high density lipoprotein cholesterol (HDL-C) levels in females at the 2-year follow-up were significantly different between the nonprogression and the progression groups. Reduction of the United Kingdom Prospective Diabetes Study (UKPDS) 10-year coronary heart disease (CHD) risk score after 2 years was generally higher in the nonprogression group than the progression group.

Conclusion

LDL-C levels in males and HDL-C levels in females at the 2-year follow-up were significantly different between participants with and without progression of carotid IMT. Furthermore, a reduction in the UKPDS 10-year CHD risk score appeared to delay the advancement of atherosclerosis. Therefore, the importance of establishing the therapeutic goal of lipid profiles should be emphasized to prevent the progression of carotid IMT in newly diagnosed T2DM patients.

Citations

Citations to this article as recorded by  
  • Comparison of the Effectiveness of Low Carbohydrate Versus Low Fat Diets, in Type 2 Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Tanefa A. Apekey, Maria J. Maynard, Monia Kittana, Setor K. Kunutsor
    Nutrients.2022; 14(20): 4391.     CrossRef
  • Nomogram Based on Risk Factors for Type 2 Diabetes Mellitus Patients with Coronary Heart Disease


    Rong Shi, Birong Wu, Zheyun Niu, Hui Sun, Fan Hu
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 5025.     CrossRef
  • HMGA1 Mediated High-Glucose-Induced Vascular Smooth Muscle Cell Proliferation in Diabetes Mellitus: Association Between PI3K/Akt Signaling and HMGA1 Expression
    Qinghai Zhang, Ling Chen, Zhibo Zhao, Ying Wu, Jing Zhong, Gebo Wen, Renxian Cao, Xuyu Zu, Jianghua Liu
    DNA and Cell Biology.2018; 37(4): 389.     CrossRef
  • Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus
    Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa, Hidenori Yoshii, Nobuichi Kuribayashi, Takeshi Osonoi, Hideaki Kaneto, Keisuke Kosugi, Yutaka Umayahara, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada
    Scientific Reports.2017;[Epub]     CrossRef
  • Impact of carotid atherosclerosis detection on physician and patient behavior in the management of type 2 diabetes mellitus: a prospective, observational, multicenter study
    In-Kyung Jeong, Sin-Gon Kim, Dong Hyeok Cho, Chong Hwa Kim, Chul Sik Kim, Won-Young Lee, Kyu-Chang Won, Doo-Man Kim
    BMC Cardiovascular Disorders.2016;[Epub]     CrossRef
  • The effect of fibroblast growth factors and advanced glycation end-products on the intima-media complex thickness in patients with coronary heart disease and type 2 diabetes
    Ekaterina Vladimirovna Ivannikova, Victor Yurievich Kalashnikov, Olga Mikhailovna Smirnova, Alexander Borisovich Kuznetsov, Сергей Anatolievich Terekhin, Alexander Viktorovich Il'in
    Diabetes mellitus.2014; 17(2): 47.     CrossRef
Autoimmune Hypoglycemia in a Patient with Characterization of Insulin Receptor Autoantibodies
Suk Chon, Moon Chan Choi, Yun Jung Lee, You Cheol Hwang, In-Kyung Jeong, Seungjoon Oh, Kyu Jeung Ahn, Ho Yeon Chung, Jeong-Taek Woo, Sung-Woon Kim, Jin-Woo Kim, Young Seol Kim
Diabetes Metab J. 2011;35(1):80-85.   Published online February 28, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.1.80
  • 5,201 View
  • 49 Download
  • 19 Crossref
AbstractAbstract PDFPubReader   
Background

Type B insulin resistance syndrome is a manifestation of autoantibodies to the insulin receptor that results in severe hyperglycemia and acanthosis nigricans. However, the mechanisms by which these autoantibodies induce hypoglycemia are largely unknown. In this paper, we report the case of patient with type B insulin resistance syndrome who presented with frequent severe fasting hypoglycemia and acanthosis nigricans.

Methods

To evaluate the mechanism of hypoglycemia, we measured the inhibition of insulin binding to erythrocytes and IM9 lymphocytes in a sample of the patient's dialyzed serum before and after immunosuppressive therapy.

Results

In the patient's pre-treatment serum IgG, the binding of 125I-insulin to erythrocytes was markedly inhibited in a dose-dependent manner until the cold insulin level reached 10-9 mol/L. We also observed dose-dependent inhibition of insulin binding to IM9 lymphocytes, which reached approximately 82% inhibition and persisted even when diluted 1:20. After treatment with glucocorticoids, insulin-erythrocyte binding activity returned to between 70% and 80% of normal, while the inhibition of insulin-lymphocyte binding was reduced by 17%.

Conclusion

We treated a patient with type B insulin resistance syndrome showing recurrent fasting hypoglycemia with steroids and azathioprine. We characterized the patient's insulin receptor antibodies by measuring the inhibition of insulin binding.

Citations

Citations to this article as recorded by  
  • Systematic Review—Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin
    Natasha Brown, Marianne S Elston
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(4): 936.     CrossRef
  • Type B insulin resistance syndrome: a systematic review
    Luizianne Mariano Martins, Virgínia Oliveira Fernandes, Manuela Montenegro Dias de Carvalho, Daniel Duarte Gadelha, Paulo Cruz de Queiroz, Renan Magalhães Montenegro
    Archives of Endocrinology and Metabolism.2020;[Epub]     CrossRef
  • Autoimmune hypoglycemia
    Marina Y. Yukina, Diana A. Davtyan, Ekaterina A. Troshina, Nurana F. Nuralieva
    Obesity and metabolism.2018; 15(3): 9.     CrossRef
  • Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody
    Simon A. Hinke, Anne M. Cieniewicz, Thomas Kirchner, Katharine D'Aquino, Rupesh Nanjunda, Jason Aligo, Robert Perkinson, Philip Cooper, Ken Boayke, Mark L. Chiu, Steve Jarantow, Eilyn R. Lacy, Yin Liang, Dana L. Johnson, Jean M. Whaley, Russell B. Lingham
    Molecular Metabolism.2018; 10: 87.     CrossRef
  • Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study
    Joanna Klubo-Gwiezdzinska, Maria Lange, Elaine Cochran, Robert K. Semple, Cornelia Gewert, Rebecca J. Brown, Phillip Gorden
    Diabetes Care.2018; 41(11): 2353.     CrossRef
  • Hypoinsulinemic Hypoglycemia Followed By The Onset Of Severe Insulin Resistance With Hyperglycemia And Circulating Anti-Insulin Receptor Antibodies In A Patient Suffering Systemic Lupus Erythematosus: A Case Report And Literature Review
    Guillermo Martínez de Pinillos, Mariana Tomé, María M. Viloria, Joaquín Bobillo, María V. Cózar
    AACE Clinical Case Reports.2017; 3(3): e284.     CrossRef
  • The treatment of hyperinsulinemic hypoglycaemia in adults: an update
    M. V. Davi′, A. Pia, V. Guarnotta, G. Pizza, A. Colao, A. Faggiano
    Journal of Endocrinological Investigation.2017; 40(1): 9.     CrossRef
  • Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report
    Lavanya Viswanathan, Imali Sirisena
    Journal of the Endocrine Society.2017; 1(12): 1435.     CrossRef
  • 反復する低血糖発作を契機に発見されたインスリン受容体異常症B型の1例(A case of type B insulin resistance presenting as recurrent hypoglycemia)
    杉本 龍 (Ryu Sugimoto), 髙木 誠 (Makoto Takaki), 前原 潤一 (Junichi Maehara), 具嶋 泰弘 (Yasuhiro Gushima)
    Nihon Kyukyu Igakukai Zasshi: Journal of Japanese Association for Acute Medicine.2017; 28(3): 100.     CrossRef
  • Type B insulin resistance syndrome
    Devina L. Willard, Mary Stevenson, Devin Steenkamp
    Current Opinion in Endocrinology, Diabetes & Obesity.2016; 23(4): 318.     CrossRef
  • Antibody-Mediated Insulin Resistance: When Insulin and Insulin Receptor Act as Autoantigens in Humans
    Christelle Liminet, Julien Vouillarmet, Karim Chikh, Emmanuel Disse
    Canadian Journal of Diabetes.2016; 40(5): 462.     CrossRef
  • The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis
    Adel A.A. Ismail
    Clinical Chemistry and Laboratory Medicine (CCLM).2016; 54(11): 1715.     CrossRef
  • Type B insulin-resistance syndrome presenting as autoimmune hypoglycemia, associated with systemic lupus erythematosus and interstitial lung disease
    Seon Mee Kang, Heung Yong Jin, Kyung Ae Lee, Ji Hyun Park, Hong Sun Baek, Tae Sun Park
    The Korean Journal of Internal Medicine.2013; 28(1): 98.     CrossRef
  • Treatment of recurrent hypoglycemia with plasmapheresis and steroid in nondiabetic patient
    Mustafa Kulaksızoglu, Mustafa Sait Gonen, Levent Kebapcilar, Fatih Sahin, Fatih Demirci, Ali Topcu
    Transfusion and Apheresis Science.2013; 48(1): 11.     CrossRef
  • A Case of Persistent Hypoglycemia: When to Think Outside the Box
    Yogeswari Venugopal, Shireene Vethakkan, Sargunan Sockalingam, Raja Jasmin, Karen Choong
    Clinical Diabetes.2013; 31(3): 130.     CrossRef
  • The effect of hyperglycemia and hypoglycemia on glucose transport and expression of glucose transporters in human lymphocytes B and T: An in vitro study
    Bożenna Oleszczak, Leszek Szablewski, Monika Pliszka
    Diabetes Research and Clinical Practice.2012; 96(2): 170.     CrossRef
  • The effect of glucose concentrations in the medium on expression of insulin receptors in human lymphocytes B and T: anin vitrostudy
    Bożenna Oleszczak, Leszek Szablewski, Monika Pliszka
    Journal of Receptors and Signal Transduction.2012; 32(5): 263.     CrossRef
  • Fulminant Type 1 diabetes in a pregnant woman as an initial manifestation of the insulin autoimmune syndrome
    H. S. Kim, T.‐Y. Lee, E. Y. Kim, J. H. Choi, S. Y. Kim, Y.‐C. Hwang, J.‐H. Kang, K. J. Ahn, H. Y. Chung, I.‐K. Jeong
    Diabetic Medicine.2012; 29(10): 1335.     CrossRef
  • A Case of the Type B Insulin Resistance Syndrome with Chronic Hepatitis B
    Hyun Seok Choi, Byoung Ho Choi, Seok Hoo Jeong, Shung Han Choi, Dong Su Shin, Sei hyun Kim, Young Sil Eom, Sihoon Lee, Yeun Sun Kim, Ie Byung Park, Ki Young Lee
    Endocrinology and Metabolism.2011; 26(4): 360.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal